BIIB34:BVMF
Biogen Inc BDR
R$162,08
0,00%
(0,00) 1D
26 ພ.ພ., 16 ໂມງ 38 ນາທີ 42 ວິນາທີ GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
໓໒,໐໙ ຕື້
Avg. vol.
໑໔,໐໐
Volume
໐,໐໐
52-wk high
R$172,26
52-wk low
R$113,64
Shares outstanding
໑໔໗,໖໔ ລ້ານ
No. of employees
໘ ພັນ
Mkt. cap
໓໒,໐໙ ຕື້
Avg. vol.
໑໔,໐໐
Volume
໐,໐໐
52-wk high
R$172,26
52-wk low
R$113,64
Shares outstanding
໑໔໗,໖໔ ລ້ານ
No. of employees
໘ ພັນ
News stories
From sources across the web
Investing.com
·
1 ມື້ກ່ອນ
Biogen to present Alzheimer’s drug data at upcoming conference
Stock Titan
·
1 ມື້ກ່ອນ
Biogen puts Alzheimer’s pipeline on display at AAIC 2026
Ad-hoc-news.de
·
3 ມື້ກ່ອນ
Biogen clears a fresh 52-week high, shares react to RayThera deal and FDA tag
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5 ພັນ
Founded1978
Headquartersແຄມບຣິກ, ມາຊາຊູເຊັດ, ສະຫະລັດ
SectorBiotechnology
Websitebiogen.com
AI content may include mistakes. Learn more